Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms

AI Briefing

• – Nectero Therapeutics presents 2-year safety and efficacy data from first-in-human trial for small- to medium-sized abdominal aortic aneurysms
• – Results showed promising outcomes with the investigational Nectero EAST System
• – Presented at Charing Cross 2026 by Dr. Andrew Holden